

**CYTOTOXIC STUDIES AND *IN VITRO* EFFECTS OF
TRANS-3,4,4',5-TETRAMETHOXYSTILBENE, A BIOACTIVE
COMPOUND ISOLATED FROM *LONCHOCARPUS PUNCTATUS* KUNTH**

**ESTUDIOS CITOTÓXICOS Y EFECTOS *IN VITRO* DE
TRANS-3,4,4',5-TETRAMETOXIESTILBENO, COMPUESTO
BIOACTIVO AISLADO DE *LONCHOCARPUS PUNCTATUS* KUNTH**

**Rocío Borges-Argáez¹; Mirbella Cáceres-Farfán¹, Nuria De Pedro²,
Bastien Cautain², José Pérez del Palacio², Francisca Vicente²,
Olga Genilloud², Angeles Melguizo², Caridad Díaz²,
Fernando Reyes², Nouredine El Aouad², y Pablo Sansores-Peraza³**

¹Centro de Investigación Científica de Yucatán, calle 43 núm. 130 Chuburná de Hidalgo, Mérida, Yucatán, 97200, Mexico. ²Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Centro de Desarrollo Farmacéutico. Avenida del Conocimiento 3, 18016, Granada, Spain. ³Facultad de Química. Universidad Autónoma de Yucatán, calle 43 núm. 613 entre 90 col. Inalámbrica CP 97069, Mérida, Yucatán, México.

Correo electrónico: rborges@cicy.mx

ABSTRACT

The bioassay-guided fractionation of *Lonchocarpus punctatus* inflorescence extracts led to the purification of the *trans* (1) and *cis* (2) isomers of 3,5-dimethoxystilbene, *trans*-3,4,4',5-tetramethoxystilbene (3), 4,4',6'-trimethoxychalcone (4) and 5-hydroxy-7,4'-dimethoxyflavone (5) as their main constituents. The structures of the compounds were established by comparing their nuclear magnetic resonance and mass spectrometry data with that from the literature. Among these metabolites, *trans*-3,4,4',5-tetramethoxystilbene (3) exhibited potent cytotoxic activity against luminal A (CC₅₀ = 2.2 μM), HER2 (CC₅₀ = 1.1 μM) and basal triple negative (CC₅₀ = 1.8 μM) breast cancer cell lines, but no cytotoxic effects were observed against immortalized hepatocyte cell lines (CC₅₀ >

50 μM), and medium (CYP3A4, CYP2C9) and low (CYP2D6) inhibitory properties were observed for P450 isoforms.

Key words: inflorescence, *Lonchocarpus punctatus*, *trans*-3,4,4',5-tetramethoxystilbene, breast cancer cell lines, cytochrome P450.

RESUMEN

El fraccionamiento biodirigido de extractos obtenidos de las inflorescencias de *Lonchocarpus punctatus* Kunth permitieron la purificación de los isómeros *trans* (1) y *cis* (2) de 3,5 dimetoxiestilbeno, *trans*-3,4,4',5-tetrametoxiestilbeno (3) 4,4',6'-trimetoxichalcona (4) y 5-hidroxi-7,4'-dimetoxiflavona (5) como sus principales constituyentes. Las estructuras de los compuestos fueron establecidas por comparación de sus datos

de resonancia magnética nuclear y espectrometría de masas con los reportados en la literatura. De todos los metabolitos aislados, *trans*-3,4,4',5-tetrametoxiestilbeno (3) exhibió potente actividad citotóxica contra las líneas celulares de cáncer luminal A ($CC_{50} = 2.2 \mu\text{M}$), HER2 ($CC_{50} = 1.1 \mu\text{M}$) y triple negativo basal ($CC_{50} = 1.8 \mu\text{M}$) pero ningún efecto citotóxico fue observado contra la línea celular immortalizada de hepatocitos ($CC_{50} > 50 \mu\text{M}$), así como propiedades inhibitorias moderadas (CYP3A4, CYP2C9) y bajas (CYP2D6) en las isoformas del citocromo P450.

Palabras clave: inflorescencia, *Lonchocarpus punctatus*, *trans*-3,4,4',5-tetrametoxiestilbene, líneas celulares cancerígenas de mama, citocromo P450.

INTRODUCTION

Breast cancer is a heterogeneous and complex disease, and it leads to most of the deaths from cancer among women throughout the world. In 2010, estimates showed that over 1.5 million women worldwide were diagnosed with breast cancer. This cancer can be classified into at least four subtypes: luminal A (MCF-7 cell line), luminal B, HER2 (HCC1954 cell line) and triple negative (Hs578t cell line) (Holliday and Speirs, 2011). Each subtype has different prognoses and treatment responses (Perou *et al.*, 2000). Different studies indicate the need for a new approach when screening potential new breast cancer therapies that use natural products. For over 40 years, natural products have remained important because they are established cancer chemotherapeutic agents. For example, antitumor compounds from microorganisms include anthracyclines, bleomycin, dactinomycin

and mitomycin C. In turn, members of four types of plant-derived compounds are widely used as antitumor agents: bisindole alkaloids, camptothecins, epipodophyllotoxins and taxanes (Kinghorn *et al.*, 2009).

During the drug discovery process, the pharmaceutical industry routinely assesses the P450 inhibition potential of drug candidates to exclude potent inhibitors from further development. Measuring the effect of new chemical entities on the activities of human cytochrome P450 marker using *in vitro* experimentation is an important experimental approach. *In vitro* drug interaction data can be used to guide the design of clinical drug interaction studies, or, when no effect is observed *in vitro*, the data can be used in place of an *in vivo* study to indicate that no interaction will occur *in vivo*. Therefore, determining the IC₅₀ values of drug candidates against major CYP450 activities is ideal for providing information to inform the decisions made during early drug discovery.

While searching for cytotoxic metabolites from the endemic flora of the Yucatan peninsula, we selected *Lonchocarpus punctatus* after using a bioassay-guided fractionation approach. *Lonchocarpus punctatus* is a common tree in the Yucatan peninsula. The Mayan names for this tree include “balché”, “x-balché”, and “saayab”. Although it is primarily an ornamental plant, its leaves are used as treatments for asthma and headache, as well as an antitussive; a mixture of its bark with honey is used as antiparasitic remedy, and the resin of this plant is used to treat stomachaches (Mendieta, 1981).

Previous phytochemical studies on *L. punctatus* have revealed the presence of

stilbenes, longystiline A, B, C, and D in the bark and root extracts; these compounds have cytotoxic activity (Gonçalves de Lima *et al.*, 1975; Marta *et al.*, 1979). Recently, we found that the ethanolic extract of the *L. punctatus* inflorescence showed cytotoxic activity against MCF-7, HCC1954 and Hs578t cancer cell lines during an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. While considering the potential of *L. punctatus* as a source of bioactive compounds, the aim of this study was to isolate, purify and identify the cytotoxic constituents of this species. Of the five isolated compounds, *trans* 3,4,4',5-tetramethoxystilbene (3) displayed the most interesting biological properties. This active compound was tested in three validated assays for human P450 marker substrate activities (diclofenac 4' α -hydroxylase for CYP2C9, dextromethorphan O-demethylase for CYP2D6 and testosterone 6 β -hydroxylase for CYP3A4 and CYP3A5) while using the approaches described in the GLP (good laboratory practices) as per the code of U.S. Federal Regulations. Additionally, 3,4,4',5-tetramethoxystilbene (3) was tested against immortalized hepatocyte cell line.

METHODS

General

The ^1H - and ^{13}C -NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer in CDCl_3 while using TMS as an internal standard. Two microlitres of the samples were analysed via LC-HRMS. The LC analysis was performed on an Agilent (Santa Clara, CA) 1200 while using a Zorbax SB-C8 column (2.1 x 30 mm). Full diode array UV scans from 100 to 900 nm

were collected in 4 nm steps at 0.25 sec/scan. The mass spectrometry data were acquired on a Bruker maXis HR-QTOF mass spectrometer (Bruker Daltonics GmbH, Bremen, Germany) coupled to the previously described LC system. The eluting solvent was ionised using the standard maxis ESI source with the drying gas flowing at 11 l/min at 200°C and a nebulizer pressure of 40 psig. The capillary voltage was set to 4000 V. The mass spectra were collected from 150 m/z to 2000 m/z in positive mode. The LR-EIMS data for compounds 2 and 4 were determined on a Hewlett Packard GC Mass selective detector.

Plant material

The inflorescences of *L. punctatus* (2 Kg) were collected in October 2011 on the road in Libre Unión-Yaxcabá, Yucatán, México. The botanical identification was performed by doctora Martha Méndez from the Unidad de Recursos Naturales. A voucher specimen was deposited in the herbarium "Roger Orellana" of the Unidad de Recursos Naturales of CICY (Collection number 1787).

Extraction and fractionation of the plant material

The inflorescence (2 kg) was macerated with ethanol for three days (3 \times), to yield 99 g of crude ethanolic extract. Partitioning the ethanolic extract (2.88 g) with hexane and mixtures of acetonitrile (CH_3CN)/MeOH yielded 900 mg of polar extract. The CH_3CN /MeOH extract was fractionated on a RediSep Rf C_{18} flash silica column (20 g) attached to a Teledyne Isco flash chromatography system. Briefly, a linear gradient of MeOH/water starting from 10% MeOH to 100% MeOH over 35 minutes was esta-

blished. The chromatogram was monitored by observing absorbance at 210 and 360 nm. Five major fractions were obtained. The fractions and the main extract were tested in an MTT based bioassay to evaluate their cytotoxicity against tumour cell lines. Fraction five displayed cytotoxic activity and was further purified by HPLC.

HPLC purification

Bioactive fraction 5 (20 mg) was subjected to semipreparative HPLC. The HPLC system (Gilson 281 serie 100878) consisted of an auto-sampler, an injector (50 µl), a pump and a UV detector. A reverse-phase C₁₈ column (250 x 9.4 mm Zorbax SB C₁₈ Agilent technologies) was employed. A gradient elution was performed with CH₃CN/H₂O mixtures from 10% CH₃CN to 60% CH₃CN over 10 minutes, followed by an isocratic elution at 60% CH₃CN for 25 minutes and a final gradual ramp to 100% CH₃CN over 10 minutes. The flow rate was 3.6 mL/min, and the ultraviolet absorbance data were observed at 210 and 305 nm (fig. 1). Repeated purification of fraction 5 allowed the isolation of compounds 1-5.

Tumour cell lines

The three breast cancer cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The Hs578t and HCC1954 monolayer cells were maintained in RPMI medium supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. The MCF-7 cells were maintained in MEM supplemented with 0.01 mg/mL bovine insulin. For the control, normal cells Fa2N4 (TebioBio) were cultured in MFE

Essential Support Medium F with MFE Culture Medium Supplement A. All cell cultures were maintained at 37°C under a humidified atmosphere of 5% CO₂.

Cytotoxicity assay

The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay test was used to evaluate the cytotoxic activity. The assay is based on the ability of drug-treated cells to reduce the yellow water-soluble MTT into a dark blue formazan product that is insoluble in water. The NADH, which is required for proper metabolic function, is provided directly by the cells. Therefore, the MTT reduction rate is an indicator of the functional integrity of the mitochondria, and, therefore, this assay measures the cellular viability. For the *in vitro* cytotoxic activity assay, 30 000 breast cancer and 20 000 Fa2N4 cells were used per well. The samples were incubated with 60-80% of confluent culture from each cell line for 24 h under 5% CO₂ at 37°C.

In the first step, each extract was tested at 1 mg/mL in triplicate (data not shown). The active extracts were tested further at different concentrations ranging from 1 to 0.0625 mg/mL in triplicate (data not showed). The pure compounds were evaluated from a starting solution of 50 µM with 1:2 dilutions. After 24 h of incubation with the extracts/fractions or 72 h with pure compounds, the optical density was measured at 570 nm with a Victor2™ Wallac spectrofluorometer.

The inhibition percentage against the tested cell line was determined by the following equation:

$$\text{Death cell percentage} = \frac{\text{OD Neg Contr} - \text{OD Sample}}{\text{OD Neg Contr} - \text{OD Pos Contr}} \times 100$$




Fig. 1. HPLC profile of active fraction of *L. punctatus* inflorescence.

where + OD_Neg Contr is the optical density of the negative control at 570 nm (0% death cell); OD_Pos Contr is the optical density of the positive control at 570 nm (100% death cell) and OD_Sample is the optical density of the samples at 570 nm. The medium with 0.5% DMSO was used as negative control, and the positive control was the medium with 4 mM of methyl methane sulfonate (MMS). The internal control curves were those from paclitaxel, doxorubicin and vorinostat (50 μ M; 1/2 dilution; 10 points).

Data presentation and analysis

The MTT data were analysed using the Genedata Screener program (Genedata AG, Switzerland). This program uses the Levenberg-Marquardt algorithm to calculate CC50 values. DMSO was used to dissolve the compounds and was used as a negative control for all cells assayed; 2 mM MMS was the positive control. In all results the RZ' factor was between 0.7-0.93.

CYP inhibition assay by HLM- LC/MS-MS method

The incubations used while evaluating the CYP inhibition were conducted in a 96-well plate format at 37°C. The final mixture (200 μ L total volume) contained 0.25 mg/mL of HLM protein in 100 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, and the test compound was used in triplicates at 0.078, 0.313, 0.625, 1.25, 2.5, 5, 11, 22, 44 and 88 μ M. The probe reaction for CYP3A4 was conducted with 50 μ M testosterone and HLM protein for 15 min. The CYP2D6 probe reaction was conducted with 22 μ M dextromethorphan for 15 min. The CYP2C9 probe reaction was conducted with 10 μ M diclofenac for 15 min.

The test compound in DMSO/CH₃CN 35/65 (v/v) (2 μ L) was combined with 98 μ L of NADPH solution, and the reactions were initiated by adding 100 μ L of the enzyme substrate solution. The reactions were terminated by adding a quench solution (90 μ L)

of CH₃CN containing the internal standards for the LC-MS/MS analysis (60 ng/ml cortisone, 100 ng/ml 4'-hydroxydiclofenac 13C6, 60 ng/ml levallorphan). Regarding the experimental design of incubation plates, eight positive controls (no inhibitor incubations) were included in each assay plate to determine the maximum amount of product formed, and, conversely, eight negative controls (no NADPH incubations) were included to assess the contribution of assay reagents to the signal readout in each assay plate. Control inhibitors, such as ketoconazole for CYP3A4, quinidine for CYP2D6, or sulfaphenazole for CYP2C9, were included in all incubation plates. The final DMSO content was established at 0.35% for all isoforms. The reaction supernatants, which were clarified by 10 min of centrifugation at 3717 G (4°C), were analysed by LC/MS-MS to obtain the relative quantities of the metabolites (6β-hydroxytestosterone, 4'-hydroxydiclofenac, or dextrorphan) generated from the corresponding probe substrates.

LC/MS-MS analysis

The quantitative analyses of the probe substrate metabolites in quenched reaction supernatant was performed using an Agilent 1190 liquid chromatograph equipped with an API4000 (triple quadrupole) mass spectrometer (AB SCIEX). The chromatographic separation was achieved using a Discovery HS C₁₈ (50 mm 2 mm, 5 μm) column (Supelco, Torrance, CA) preceded by a Discovery HS C₁₈ precolumn. The column temperature was 25°C. The mobile phase consisted of two solvents: (A) water/MeOH 90/10 (v/v) in 0.1% formic acid and (B) CH₃CN/water 90/10 (v/v) with 0.1% formic acid. Mobile phase B was held at 10% for 0.5 minutes before being increased to 45% B for 1.50

minutes. This solvent composition was held for 0.30 minutes before being increased again to 95% B for 2.30 minutes, held for 0.50 minutes, and returned to 10% B for 0.10 minutes for re-equilibration, which occurred for 0.61 minutes. The total run time was 3.51 minutes, and the flow rate was 1 mL/min. The mass spectrometer was operated with APCI ionization probe in positive mode using the multiple reaction-monitoring scanning mode. The reaction product and internal standard peak areas were integrated using the Analyst software.

Data analysis

All of the IC₅₀ values and solubility limits were calculated using the GeneData Screener application software. The equation used for normalizing the CYP inhibition data is as follows:

$$\%PC = (x-NC)/(PC-NC)*100$$

where %PC is the percentage of activity remaining at a particular concentration after normalization, NC is the median of the measured signal values for the negative control wells on a plate, PC is the median of the measured signal values for the positive control wells on a plate, and x is the measured raw signal value of a well. The normalized data were fitted with a smart engine embedded in the core of the GeneData Screener while using a four-parameter logistic fit to determine the IC₅₀ values.

RESULTS

The ethanolic extract (EtOH) of the inflorescence from *L. punctatus* showed cytotoxic activity against MCF-7 (CC₅₀ = 0.22 mg/mL), HCC1954 (CC₅₀ = 0.14 mg/mL) and

Hs578t ($CC_{50} = 0.06$ mg/mL) breast cancer cell lines during a preliminary evaluation. A separation of the EtOH extract by C_{18} reversed-phase chromatography afforded five main fractions. A bioassay-guided isolation led to the purification of the five major components present in the active fraction (fig. 2). **Metabolite 1**, obtained as a pale yellow oil, was isolated together with metabolite 2. Both showed a pink colour upon spraying with a solution of 20% phosphomolibdic acid and UV spectrum characteristic of stilbenes. Metabolite 1 showed a molecular formula of $C_{16}H_{16}O_2$ which was deduced by its LC-HRMS (m/z 241.1223 [$M + 1^+$]; Calcd 240.1141). The 1H NMR spectrum of 1 presented two methines at δ 7.07 (*d*, $J = 16.3$ Hz) and δ 7.09 (*d*, $J = 16.3$ Hz) indicative of a *trans*-double bond. Three aromatic protons at δ 6.68 (2H, *d*, $J = 2.2$ Hz) and δ 6.41 (1H, *t*, $J = 2.2$ Hz), two methoxyl signals at δ 3.84 (s, 6H), and five aromatic protons between δ 7.27 and δ 7.52 corresponding to a monosubstituted aromatic ring.

Metabolite 2, isolated as a pale yellow oil, appeared very similar to metabolite 1, but all the signals were somewhat upfield shifted with respect to those of 1. The only difference between the two metabolites was the coupling constant measured for the vinyl protons of 2 ($J = 12.0$ Hz). These spectroscopic data are characteristic of unsymmetrical *trans* ($J = 16.0$ Hz) and *cis* ($J = 12.0$ Hz) isomers of 3,5-dimethoxystilbene. The structures of metabolites 1 and 2 were confirmed by comparison with the stilbenes reported from the bark of some *Pinus* species and in commercial soy proteins (Boatright *et al.*, 1998).

Metabolite 3, isolated as a yellow oil, showed a molecular ion peak at m/z 301.1443 [$M + 1^+$] (Calcd 300.1363) from its LC-HRMS, corresponding to a molecular formula of $C_{18}H_{20}O_4$. It was characterized by the presence of signals corresponding to a disubstituted *trans* double bond (doublets at δ 6.56 and δ 6.63 with $J = 16.1$ Hz) in




Fig. 2. Metabolites isolated from the inflorescence of *L. punctatus*.

its ^1H NMR (fig. 2). The UV absorption suggested the presence of a skeleton of a stilbene in the molecule, whose substituents were four methoxyl groups as seen by ^1H NMR. Other signals present in the ^1H NMR spectrum and their multiplicities support the identification of three as *trans* 3,4,4',5-tetramethoxystilbene (fig. 3). This metabolite has been previously isolated from leaves of *Piper caninum* (Farediah *et al.*, 1997). **Metabolites 4** and **5** were isolated as yellow needles and were identified as 5-hydroxy-7,4'-dimethoxyflavone and 5,7,4'-trimethoxychalcone, respectively. The former was previously isolated from

Biota orientalis and the latter was reported from *Crotalaria ramossisima* (Hyun *et al.*, 1995; Lai *et al.*, 2010).

The isolates (1-5) were tested for cytotoxicity against the three human breast cancer cell lines while using paclitaxel, vorinostat and doxorubicin as positive controls. Additionally, a healthy hepatocyte cell line (Fa2N4) was included to evaluate the hepatotoxicity of the actives compounds. The results are summarized in table 1.

No cytotoxic effect was observed with compounds 1, 2 and 5; however 3,4,4',5-




Fig. 3. ^1H NMR spectrum of *trans*-3,4, 4',5-tetramethoxystilbene (3) (400 MHz, CDCl_3).

tetramethoxystilbene (3) and 4,4',6'-trimethoxychalcone (4) were the active principles present in the EtOH extract of *L. punctatus*. In addition, 3,4,4',5-tetramethoxystilbene (3) had the highest cytotoxic activity (CC₅₀ values between 1 and 2.2 µM) and no cytotoxicity against the Fa2N4 cell lines versus 4,4',6'-trimethoxychalcone (4). In fact, 3,4,4',5-tetramethoxystilbene (3) showed CC₅₀ values lower than those of Paclitaxel when tested against the Hs5787 cell line, similar to Vorinostat in all tumoural cell lines, but it has no effect against a healthy cell line (Fa2N4). Due to the different behaviours of this compound against tumoural and non-tumoural cell lines, we will study 3,4,4',5-tetramethoxystilbene in greater detail.

The *in vitro* inhibition data for *trans* 3,4,4',5-tetramethoxystilbene in specific human CYP enzymes (CYP, 2C9, 2D6, and 3A4) was obtained using the previously described validated assays; this compound displayed medium inhibitory properties on the CYP3A4 (IC₅₀ = 2.95±0.53 µM) and

CYP2C9 (IC₅₀ = 6.48±0.04 µM) isoforms and a low inhibition on the CYP2D6 (IC₅₀ > 34.00 µM) isoform. Because the inhibitory potency (IC₅₀) was >1 µM in all cases, an *in vivo* drug-drug interaction would not be observed; for CYP3A4 and CYP2C9, however, the inhibitory potency was between 1 µM and 10 µM, indicating that the *trans*-3,4,4',5-tetramethoxystilbene (3) might interact with other drugs metabolized via CYP3A4 and CYP2C9. Fortunately, these results indicate that multiple metabolic pathways are available to *trans*-3,4,4',5-tetramethoxystilbene, decreasing the risk of DDI.

Stilbenes are a group of metabolites commonly found in higher plants, especially in the leguminose family. These compounds have demonstrated multiple chemopreventive properties including the inhibition of the three major stages of tumour formation: the initiation, promotion and progression phases (Jang *et al.*, 1997). Methoxystilbenes have demonstrated cytotoxic activities. In fact, 3,4,4',5-tetramethoxystilbene and

Table 1. Cytotoxic activity of the constituents of *L. punctatus* inflorescence^a

Compound ^a	MCF-7	Hcc1954	Hs578t	Fa2N4
1	> 50.00	> 50.00	> 50.00	> 50.00
2	> 50.00	> 50.00	> 50.00	48.20 ± 3.25
3	2.20 ± 0.11	1.10 ± 0.07	1.80 ± 0.26	> 50.00
4	4.80 ± 0.75	0.80 ± 0.09	1.13 ± 0.32	4.60 ± 0.81
5	> 50.00	> 50.00	> 50.00	31.20 ± 2.50
Paclitaxel	--	< 0.10	40.02 ± 2.60	< 0.10
Vorinostat	6.80 ± 1.20	5.90 ± 0.95	1.67 ± 0.42	4.30 ± 0.98
Doxorubicin	0.86 ± 0.12	0.96 ± 0.07	0.16 ± 0.07	0.47 ± 0.09

^a Results are expressed as CC₅₀ values (µM)

trans 2,3',4,5'-tetrametoxystilbene are potent apoptosis-inducing agents with clinical potential (Robeti *et al.*, 2003). Among the other methoxystilbenes, 2,3',4,4',5'-penta-metoxystilbene is a potently induces apoptosis in colon cancer cells by targeting the microtubules (Li *et al.*, 2009). This report is the first to describe the cytotoxic activities of inflorescence extracts of *L. punctatus*.

CONCLUSIONS

A bioactivity-guided approach identified *trans*-3,4,4',5'-tetrametoxystilbene (3) and 4,4',6'-trimetoxychalcone (4) as the active principles of the inflorescence extract of *L. punctatus*. These compounds could account for most of the cytotoxic activity founded in this species. Tetrametoxystilbene (3) exhibited potent cytotoxic activity against breast cancer cell lines, but its lack of cytotoxic effects against immortalized hepatocyte cell lines (CC50 > 50 μ M), as well as its medium (CYP3A4, CYP2C9) and low (CYP2D6) inhibitory properties on P450 isoforms, make it a good candidate for further studies.

ACKNOWLEDGEMENTS

The authors wish to gratefully acknowledge CONACYT Mexico for their financial support of R. Borges-Argáez during her sabbatical project. The authors are grateful to doctora Martha Mendez-González, Jesús Martín, Gloria Crespo-Sueiro and Ignacio Pérez for their technical assistance. This work was supported by the Fundación MEDINA, which is a public-private partnership of Merck Sharp & Dohme, the University of Granada and Junta de Andalucía in Granada, Spain.

LITERATURE CITED

- Boatright, W.L.; J. St. Pyrek, J. Song, y A.D. Crum, 1998. "Identification of *trans*-3,5-dimetoxystilbene in commercial soy protein isolates". *Journal of American Oil Chemical Society*, **75**: 1651-1655.
- Farediah, A.; A.B. Sohana, A.I. Zainuddin, y R.W. Read, 1997. "Constituents of the leaves of *Piper caninum*". *Planta Medica*, **63**: 193-194.
- Gonçalves de Lima, O.; G.B. Marini- Bettola, M. Sousa, J.F. De Mello, E.C. Da Silva, L.L. De Oliveira, y C.T. Cotias, 1975. "Antimicrobial substances from higher plants. XLVI. Initial observations on biological effects of extracts from the stem bark and root bark of *Lonchocarpus violaceus* (*L. longistylus*), a Mexican Mayan, Guatemalan and Honduran plant". *Revista Institucional de Antibióticos*. Universidad Federal Pernambuco Recife, **15**: 3-15.
- Holliday, D.L., y V. Speirs, 2011. "Choosing the right cell line for breast cancer research". *Breast Cancer Research Breast Cancer Research*, **13**: 215-216.
- Hyun, O.Y.; S. Dae-Yeon, y H.H. Byung, 1995. "Isolation and Characterization of Platelet-Activating Factor Receptor Binding Antagonist from Biota orientalis". *Planta Medica*, **61**: 37-40.
- Jang, M.; L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher,

- H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moo, y J.M. Pezutto, 1997. "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes". *Science*, **275**: 218-220.
- Kinghorn, D. A.; C. Young-Won, y S.M. Swanson, 2009. "Discovery of Natural Product Anticancer Agents from Biodiverse Organisms". *Current Opinion in Drug Discovery & Development*, **12**: 189-196.
- Lai, C.H.; Y.K. Rao, S.H. Fang, Y.T. Sing, y Y.M. Tzeng, 2010. "Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of *Helicobacter pylori*-induced inflammation". *Bioorganic & Medicinal Chemistry Letters*, **20**: 5462-5465.
- Li, H.; W.W. Ka-Kei, Z. Zheng, C. Tao-Che, L. Yu, Z. Jie-Li, Y. Chun-Wu, K.W. Cheng, J. Yu, C. Hin-Cho, y M. Wang, 2009. "2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules". *Biochemical Pharmacology*, **7**(8): 1224-1232.
- Marta, M.; A. Lupi, G. Di Chiara, M.F. Delle, y G.B. Marini-Bettolo, 1979. "Synthesis of longistyline A, B, C, D and other new prenylated stilbenes". *Gazzeta Chimica Italiana*, **109**: 323-324.
- Mendieta, R.M, y S. Del Amo, 1981. *Plantas medicinales del estado de Yucatán*. Instituto Nacional de Investigación sobre Recursos Bióticos. First ed. Compañía Editorial Continental, Distrito Federal, México.
- Perou, C.M.; T. Sùrlie, M.B. Eisen, M. van de Rijn, S.S. Jeffreyk, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L. Akslen, O. Flugel, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lunning, A.L. Burren-Dale, P.O. Brown, y D. Botstein, 2000. "Molecular portraits of human breast tumours". *Nature*, **406**: 747-752.
- Robeti, M.; D. Pizziranti, D. Simoni, R. Rondanin, R. Baruchello, y C. Bonora, 2003. "Synthesis and biological evaluation of resveratrol and analogues as apoptosis inducing agents". *Journal of Medicinal Chemistry*, **46**: 3546-3554.